We typically think of biologically relevant protein complexes forming spontaneously through surface complementarity. However, with the discovery of the mechanism of action (MoA) of Rapamycin & Cyclosporin in the early nineties, it became apparent that protein-protein interactions (PPIs) could be mediated by non-proteinaceous molecules. Furthermore, such interactions could have beneficial pharmacological effects such as the inhibition of the central regulatory kinase mTOR. Since this initial ground-breaking discovery, many other molecules…
Contributing All the Way to the Clinic
Recently the ZoBio team made an important contribution to a drug discovery project for our client Mirati Therapeutics that we are particularly proud of and has had significant impact [1]. This work describes a program to develop inhibitors of the epigenetic target PRMT5 with the potential to …
Drug Discovery Chemistry
Hybrid Drug Discovery Chemistry is a dynamic conference for medicinal chemists working in pharma and biotech. Focused on discovery and optimization challenges of small molecule drug candidates, this event provides many exciting opportunities for scientists. Our CEO Gregg Siegal attended the event and participated in many interesting and educational discussions. Conference website
8th RSC-BMCS Fragment-based Drug Discovery Meeting
Hybrid ZoBio attended the 8th RSC-BMCS Fragment-based Drug Discovery meeting which was taking place in Cambridge on the 27-29 March 2022. The meeting focused on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programs. Great scientific program and fantastic atmosphere delivered a truly memorable conference!…